Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis
Open accessAbstract
Summary: Background & Aim: Non‐alcoholic fatty liver disease (NAFLD), and especially fibrotic non‐alcoholic steatohepatitis, is associated with high risks of liver‐related events (LRE) and extrahepatic events (EHE). We evaluated the competitive risk occurrence of LRE and EHE in a large cohort of biopsy‐proven NAFLD stratified according to baseline severity of fibrosis. Methods: Two thousand one hundred thirty‐five patients with biopsy‐proven NAFLD were enrolled. Observed cumulative incidence functions (CIFs) were used to evaluate the risk of LRE and EHE; cause‐specific Cox model and predicted CIFs were fitted to identify predictors of LRE and EHE. A replication cohort of NAFLD patients with liver fibrosis severity estimated by liver stiffness measurement by transient elastography was also enrolled. Results: Observed CIFs indicated that the 60‐month probabilities of LRE and EHE were 0.2% and 3% in F0‐F1, 2% and 3.8% in F2 and 9.7% and 6.4% in F3‐F4 patients, respectively. The cause‐specific Cox model indicated that in F0‐F1 and F2 patients, age > 50 years (HR 2.7) was the only predictor of LRE, while age > 50 years (HR 2.96), previous cardiovascular events (CVE, HR 2.07), and previous extra‐hepatic cancer (HR 2.36) were independent risk factors for EHE. In F3‐F4 patients, age > 55 years (HR 1.73), obesity (HR 1.52), PLT < 150 000/mmc (HR 3.66) and log(GGT) (HR 1.77) were associated with LRE, while age > 55 years (HR 1.74) and previous CVE (HR 2.51) were independent predictors of EHE. Predicted CIFs for HE and EHE in F0‐F1, F2 and F3‐F4 patients stratified the risk of events. The results were externally replicated. Conclusion: The likelihood of EHE in NAFLD patients is relevant and increases according to the severity of liver fibrosis, while the risk of LRE is negligible in F0‐F1, low but clinically relevant in F2 and high in F3‐F4 patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most patients with non-advanced NAFLD (fibrosis stage 0-2) primarily show extrahepatic events during follow-up, and the predominant cause of death in these patients is cardiovascular disease rather than liver-related events.
“most patients with non‐advanced NAFLD (i.e. Fibrosis Stage 0–2) primarily show extrahepatic events during follow‐up and the predominant cause of death in these patients derives from cardiovascular disease rather than from liver‐related events [7, 8].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [8]
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286 · see citing works
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · see citing works
Self-citationYounossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802 · see citing works
White, D. L., Kanwal, F., & El–Serag, H. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.001 · Cited by 766 · see citing works
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · cited 1× · see citing works
“Notably, our data from F2 patients add further insights regarding the risk of developing HCC in patients with NASH but without cirrhosis,30-33 even if systematic screening in these patients cannot be suggested.34-36 A recent multicentre study18 used a competitive risks model to evaluate the…”
BackgroundBoursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400 · see citing works
Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336 · see citing works
Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.327 · Cited by 280 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305 · see citing works
- Authors
- Pennisi, G., Enea, M., Romero‐Gomez, M., Viganò, M., Bugianesi, E., Wong, V. W. ‐., Fracanzani, A. L., Sebastiani, G., Boursier, J., Berzigotti, A., Eslam, M., Ampuero, J., Benmassaoud, A., La Mantia, C., Mendoza, Y. P., George, J., Craxì, A., Camma', C., de Ledinghen, V., & Petta, S.
- Affiliations
- Palermo Italy
- Seville Spain
- Milan Italy
- Turin Italy
- Hong Kong China
- Montreal Quebec Canada
- Angers France
- Bern Switzerland
- Sydney New South Wales Australia
- Pessac France
- Corresponding author
- Petta, Salvatore
- ORCID
- Pennisi, Grazia
- Enea, Marco
- Romero‐Gomez, Manuel
- Viganò, Mauro
- Bugianesi, Elisabetta
- Wong, Vincent W.‐S.
- Fracanzani, Anna Ludovica
- Sebastiani, Giada
- Boursier, Jerome
- Berzigotti, Annalisa
- Eslam, Mohammed
- Ampuero, Javier
- Benmassaoud, Amine
- Mendoza, Yuly P.
- George, Jacob
- Camma', Calogero
- de Ledinghen, Victor
- Petta, Salvatore
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2022-01-05
- Volume
- 55
- Issue
- 5
- Pages
- 604-615
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W4206151377
- Cited by
- 43
- References
- 8
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 11 · 2023: 11 · 2022: 8
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver-related events, liver fibrosis severity, competing risks, cardiovascular events, extrahepatic cancer, liver stiffness measurement, transient elastography, risk factors, platelet count, gamma-glutamyl transferase, obesity, age, cumulative incidence function
- MeSH terms
- Biopsy, Fibrosis, Humans, Liver, Liver Cirrhosis, Middle Aged, Retrospective Studies, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review